0001193125-11-163010.txt : 20110610 0001193125-11-163010.hdr.sgml : 20110610 20110610163150 ACCESSION NUMBER: 0001193125-11-163010 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20110516 ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20110610 DATE AS OF CHANGE: 20110610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TIBET PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001489077 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35038 FILM NUMBER: 11905988 BUSINESS ADDRESS: STREET 1: 90 JAFFE ROAD STREET 2: ROOM 1701, 17/F CITY: WANCHAI STATE: K3 ZIP: 00000 BUSINESS PHONE: 852 9798 5569 MAIL ADDRESS: STREET 1: 90 JAFFE ROAD STREET 2: ROOM 1701, 17/F CITY: WANCHAI STATE: K3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Shangri-La Tibetan Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20100412 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2011

 

 

Tibet Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

British Virgin Islands   001-35038   Not Applicable

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

Room 1701, 17/F

90 Jaffe Rd.

Wanchai, Hong Kong

(Address of Principal Executive Office) (Zip Code)

(852) 9798 5569

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


ITEM 5.01 CHANGE IN CONTROL OF REGISTRANT

In anticipation of the resignation of Mr. Taylor Z. Guo as Chief Executive Officer (“CEO”) of Registrant and the appointment of Mr. Hong Yu as the Registrant’s new CEO, Mr. Guo, Mr. Yu and eight other shareholders of the Registrant entered into a “Voting Rights Revocation” agreement on May 16, 2011 by which they mutually agreed to revoke and terminate a former March 30, 2010 “Voting Agreement” among them. The March 30, 2010 Voting Agreement had been entered into to facilitate the Registrant’s initial public offering, and had vested in Mr. Guo beneficial ownership of 38% of the then issued and outstanding shares of Registrant, consisting of 150,000 shares he owned directly and 4,334,500 shares of the eight other shareholders to which he held voting rights under the Voting Agreement. By reason of Voting Rights Revocation, Mr. Guo no longer holds voting rights to any shares other than the 150,000 shares he owns directly. As Mr. Guo surrendered rather than acquired any controlling interest in Registrant, he paid no consideration and did not contribute any funds. Upon the effectiveness of the Voting Rights Revocation agreement, the principal shareholder of the Registrant and the only shareholder holding more than 5% of issued and outstanding shares is Mr. Yu, the chairman of its board of directors and its new CEO. Mr. Yu’s ownership interest remains unchanged at 3,280,000 shares. As is shown in the table below, as of the date of this filing, Mr. Yu is the only shareholder of Registrant holding more than 5% of the issued and outstanding shares of Registrant, with 22.1% of its 14,845,834 issued and outstanding shares.

 

Title of
class

  

Name and address of beneficial

owner

  

Amount and nature of beneficial

ownership

   Percent of
class
 

Common

   Hong Yu1    3,280,000      22.1 %. 

 

1. Mr. Yu’s address is: Hong Yu, c/o Tibet Pharmaceuticals, Inc., Room 1701, 17/F, 90 Jaffe Rd., Wanchai, Hong Kong.

 

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

(b) By a written “Termination Agreement” dated June 6, 2011, Mr. Taylor Z. Guo resigned as the CEO of the Registrant, and the Registrant accepted Mr. Guo’s resignation. Mr. Guo’s separation from the Registrant was not the result of any disagreement. Mr. Guo also resigned as the General Manager/CEO of Registrant’s operating entity in China, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (“YSTP”). Mr. Guo continues to serve as a director of the Registrant. A translation of the Termination Agreement is attached as an exhibit hereto.

(c) By a written “Employment Agreement” dated June 6, 2011, the Registrant formally retained Mr. Hong Yu to serve as the CEO of the Registrant. Mr. Yu also assumed the duties of the CEO of Registrant’s operating entity, YSTP. Mr. Yu is the founder of YSTP and the largest shareholder of Registrant; he also has been serving and continues to serve as the chairman of the board of directors of both companies. The Employment Agreement provides that Mr. Yu’s duties as CEO of Registrant commenced on June 6, 2011 and, unless sooner terminated, shall remain in force for a period of three years, and the end of which the agreement would be renewed automatically for successive one-year terms unless either party gave 30-days prior written notice of expiration. The Employment Agreement further provides that he will be entitled to a base salary of $30,000, subject to annual review as well as certain benefits, and also will be eligible for incentive bonuses. A translation of the Employment Agreement is attached as an exhibit hereto.

The assumption by Mr. Yu of the duties of CEO of Registrant follows upon Mr. Guo’s resignation as CEO. The two individuals and the Registrant coordinated the transition through Mr. Guo’s Termination Agreement and Mr. Yu’s Employment Agreement, both effective June 6, 2011.

Mr. Yu does not have any family relationships with any other director of officer of Registrant, or any person nominated to become a director or executive officer of Registrant.

In further response to this Item 5.02(c), Registrant incorporates by reference the “Management” and “Related Party Transactions” sections of the registration statement filed with the Commission on May 14, 2010, as amended (file no. 333-166854) (the “Registration Statement”) and the prospectus filed pursuant to Rule 424(b)(3) of the Securities Act of 1933 (the “Securities Act”) on January 11, 2011 (the “IPO Prospectus”), as well as the section entitled “Item 13. Certain Relationships and Related Transactions, and Director Independence” in Registrant’s Form 10K filed with the Commission on March 30, 2011 (file no. 001-35038).


ITEM 8.01 OTHER EVENTS

On June 10, 2011, the Registrant issued a press release announcing the assumption by Mr. Hong Yu as the duties of the Chief Executive Officer (“CEO”) of Registrant in addition to his duties as the chairman of the Registrant’s Board of Directors, and also announcing the resignation of Taylor Z. Guo as the CEO of Registrant.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

 

(a) Financial statements of businesses acquired.

Not Applicable.

 

(b) Pro forma financial information.

Not Applicable.

 

(c) Shell company transactions.

Not Applicable.

 

(d) Exhibits.

 

10.01    Translation of Termination Agreement between Registrant and Taylor Z. Guo dated June 6, 2011.
10.02    Translation of Employment Agreement between Registrant and Hong Yu dated June 6, 2011.
99.01    Press Release of June 10, 2011: “Tibet Pharmaceuticals Announces New CEO.”


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Tibet Pharmaceuticals, Inc.
Date: June 10, 2011   By:  

      /s/ Hong Yu

          Hong Yu
          Chief Executive Officer


EXHIBIT INDEX

 

Number

  

Description of Exhibit

10.01    Translation of Termination Agreement between Registrant and Taylor Z. Guo dated June 6, 2011.
10.02    Translation of Employment Agreement between Registrant and Hong Yu dated June 6, 2011.
99.01    Press Release of June 10, 2011: “Tibet Pharmaceuticals Announces New CEO.”
EX-10.01 2 dex1001.htm EXHIBIT 10.01 Exhibit 10.01

Exhibit 10.1

Termination Agreement

This TERMINATION AGREEMENT (hereinafter referred to as the “Agreement”) is entered into on June 6 , 2011 by and between:

Tibet Pharmaceuticals, Inc., a company legally incorporated under the laws of British Virgin Islands and listed in NASDAQ, having a principal executive office at Room 1701, 17/F 90 Jaffe Rd. Wanchai, Hong Kong (hereinafter referred to as “TBET”)

AND:

Taylor Z. Guo, a citizen of PRC with Passport number G02189821 (hereinafter referred to as the “Taylor”)

(TBET and Taylor hereinafter collectively referred to as “Parties”)

1. PREAMBLE

WHEREAS, prior to the Termination Date provided in this Agreement, Taylor served as CEO for TBET;

WHEREAS, Taylor wishes to resign as CEO of TBET, and TBET agrees to discharge Taylor from his current position as CEO of TBET;


THEREFORE, THE PARTIES AGREE AS FOLLOWS:

2. TERMINATION OF EMPLOYMENT

2.1 Termination Date

The parties agree that Taylor’s employment with the TBET will terminate on June, 6 , 2011 (hereinafter referred to as the “Termination Date”).

2.2 Severance Pay

The Parties agree that there is no severance pay to be paid to Taylor by TBET.

3. SETTLEMENT AND RELEASE

Taylor hereby irrevocably and unconditionally releases and discharges TBET from any and all claims, known or unknown, which he, his heirs, successors or assigns have or may have against releases and any and all liability which releases may have to him whether denominated as claims, demands, causes or action, obligations, damages, or liabilities arising from any and all bases.

This release is for any relief, no matter how denominated, including, but not limited to, back pay, front pay, compensatory damages, punitive damages, or damages for pain and suffering.

4. PENDING FUTURE LITIGATION

Taylor agrees to participate in any future litigation arising out of the period of his employment with TBET by giving advice, participating in discovery, and giving deposition and trial testimony as may be necessary, as well as participation in other activities related to such litigation.

If Taylor is required to participate in either pending or future litigation, TBET agrees to reimburse Taylor for all out-of-pocket expenses reasonably incurred in connection therewith.


5. COMMITMENT TO CONFIDENTIALITY AND NONDISCLOSURE

For a period of 36 months from the Termination Date, Taylor is committed to TBET to:

a) keep confidential and not disclose the information;

b) take and implement all appropriate measures to protect the confidentiality of the information;

c) not disclose, transmit, exploit or otherwise use for its own account or others.

6. NON-COMPETITION

For a period of 12 months from the Termination Date, Taylor makes a commitment to TBET that it shall not render services to or for direct or indirect competitors of TBET.

7. NON-SOLICITATION

Taylor covenants and agrees that during the period ending 24 months after the Termination Date, he will not, directly or indirectly, hire, solicit, or encourage then-current TBET employees to apply for employment with any person or entity: (a) with which Taylor is (or intends to be) employed; (b) in which Taylor or a firm in which he is employed, has a financial interest or is engaged as a consultant, recruiter, independent contractor or otherwise; or (c) in which Taylor is otherwise substantially financially interested.

Taylor further covenants and agrees that he will not provide to any other person or entity the names of or references (other than a reference requested by TBET) on any person who is then employed by TBET.


The Parties agree that if in any proceeding, the tribunal shall refuse to enforce fully any covenants contained herein because such covenants cover too extensive a geographic area or too long a period of time or for any other reason whatsoever, any such covenant shall be deemed amended to the extent (but only to the extent) required by law.

8. EFFECTIVE DATE OF AGREEMENT

This Agreement shall enter into force on the Termination Date provided in clause 2.1.

Tibet Pharmaceuticals, Inc.

 

By:     /s/ Hong Yu           (Signature)
  Hong Yu  
Title:   Chairman  

 

By:     /s/ Taylor Z. Guo           (Signature)
  Taylor Z. Guo  
EX-10.02 3 dex1002.htm EXHIBIT 10.02 Exhibit 10.02

Exhibit 10.2

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into June 6 , 2011 (the “Effective Date”), by and between TIBET PHARMACEUTICALS, INC., a company incorporated and existing under the laws of the British Virgin Islands (the “Company” and, together with all of its direct or indirect parent companies, subsidiaries, affiliates, or subsidiaries or affiliates of its parent companies, collectively referred to as the “Company Group”), and Yu Hong, an individual (the “Executive”).

RECITALS

THE PARTIES ENTER THIS AGREEMENT on the basis of the following facts, understandings and intentions:

A. The Company desires that the Executive be employed by the Company to carry out the duties and responsibilities described below, all on the terms and conditions hereinafter set forth.

B. The Executive desires to accept such employment on such terms and conditions.

NOW, THEREFORE, in consideration of the above recitals incorporated herein and the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby expressly acknowledged, the parties agree as follows:

1.Retention and Duties.

1.1 Retention. The Company does hereby hire, engage and employ the Executive for the Period of Employment (as defined in Section 2) on the terms and conditions expressly set forth in this Agreement. The Executive does hereby accept and agree to such hiring, engagement and employment, on the terms and conditions expressly set forth in this Agreement. The Executive agrees to commence active employment with the Company on or before June 6 , 2011 (the first day of such employment is referred to as the “Employment Commencement Date”).

1.2 Duties. During the Period of Employment, the Executive shall serve the Company as its Chief Executive Officer (the “CEO”) and shall have such powers, duties and obligations consistent with such position as the Company’s Board of Directors (the “Board”) shall determine from time to time. The Executive shall be subject to such directives of the Board and the corporate policies of the Company as they are in effect from time to time throughout the Period of Employment (including, without limitation, the Company’s business conduct and ethics policies, as they may change from time to time). During the Period of Employment, the Executive shall report solely to the Board of the Company.

1.3 No Other Employment; Minimum Time Commitment. During the Period of Employment, the Executive shall both (i) devote substantially all of the Executive’s business time, energy and skill to the performance of the Executive’s duties for the Company, and (ii) hold no other employment. The Executive’s service on the boards of directors (or similar body) of other business entities is subject to the approval of the Board. The Company shall have the right to require the Executive to resign from any board or similar body which he may then serve if the Board reasonably determines in writing that the Executive’s service on such board or body interferes with the effective discharge of the Executive’s duties and responsibilities to the Company or that any business related to such service is then in competition with any business of the Company or any of its affiliates, successors or assigns.


1.4 No Breach of Contract. The Executive hereby represents to the Company that: (i) the execution and delivery of this Agreement by the Executive and the Company and the performance by the Executive of the Executive’s duties hereunder shall not constitute a breach of, or otherwise contravene, the terms of any other agreement or policy to which the Executive is a party or otherwise bound; (ii) that the Executive has no information (including, without limitation, confidential information and trade secrets) relating to any other person or entity which would prevent, or be violated by, the Executive entering into this Agreement or carrying out his duties hereunder; (iii) that the Executive is not bound by any confidentiality, trade secret or similar agreement (other than this Agreement) with any other person or entity.

2. Period of Employment. The “Period of Employment” shall be a period of three (3) years commencing on the Employment Commencement Date and ending at the close of business on the third (3rd) anniversary of the Employment Commencement Date (the “Termination Date”); provided, however, that this Agreement shall be automatically renewed, and the Period of Employment shall be automatically extended for one (1) additional year on the Termination Date and each anniversary of the Termination Date thereafter, unless either party gives notice, in writing, at least thirty (30) days prior to the expiration of this Agreement and the Period of Employment (including any renewal thereof) of such party’s desire to terminate the Agreement or modify its terms. The term “Period of Employment” shall include any extension thereof pursuant to the preceding sentence. Provision of notice that the Period of Employment shall not be extended or further extended, as the case may be, shall not constitute a breach of this Agreement and shall not constitute “Constructive Termination” for purposes of this Agreement. Notwithstanding the foregoing, the Period of Employment is subject to earlier termination as provided below in this Agreement.

3. Compensation.

3.1 Base Salary. The Executive’s base salary (the “Base Salary”) during the Period of Employment shall be paid in accordance with the Company’s regular payroll practices in effect from time to time, but not less frequently than in monthly installments. The Executive’s Base Salary for the first twelve (12) months of the Period of Employment shall be at an annualized rate of USD30,000. The Company will review the Executive’s Base Salary at least annually. The Company will set the Executive’s rate of Base Salary for any portion of the Period of Employment after the first twelve (12) months thereof.

3.2 Incentive Bonus. During the Period of Employment, the Executive shall be eligible to receive periodic incentive bonuses under any incentive program applicable to executive officers of the Company and approved by the Board (the “Incentive Bonus”).

4. Benefits.

4.1 Retirement, Welfare and Fringe Benefits. During the Period of Employment, the Executive shall be entitled to participate in all employee pension and welfare benefit plans and programs, and fringe benefit plans and programs, made available by the Company to the Company’s employees generally, in accordance with the eligibility and participation provisions of such plans and as such plans or programs may be in effect from time to time.


4.2 Reimbursement of Business Expenses. The Executive is authorized to incur reasonable expenses in carrying out the Executive’s duties for the Company under this Agreement and reimbursement for all reasonable business expenses the Executive incurs during the Period of Employment in connection with carrying out the Executive’s duties for the Company, subject to the Company’s expense reimbursement policies in effect from time to time.

4.3 Vacation and Other Leave. During the Period of Employment, the Executive shall accrue and be entitled to take paid vacation in accordance with the Company’s vacation policies in effect from time to time, including the Company’s policies regarding vacation accruals; provided that the Executive’s rate of vacation accrual during the Period of Employment shall be no less than three (3) weeks per year. The Executive shall also be entitled to all other holiday and leave pay generally available to other executives of the Company.

5. Termination.

5.1 Termination by the Company. The Executive’s employment by the Company, and the Period of Employment, may be terminated at any time by the Company: (i) with Cause (as defined in Section 5.5), or (ii) with no less than thirty (30) days advance notice to the Executive, without Cause, or (iii) in the event of the Executive’s death, or (iv) in the event that the Board determines in good faith that the Executive has a Disability (as defined in Section 5.5).

5.2 Termination by the Executive. The Executive’s employment by the Company, and the Period of Employment, may be terminated by the Executive with no less than thirty (30) days advance notice to the Company; provided, however, that in the case of a Constructive Termination (as defined herein), the Executive may provide immediate written notice if the Company fails to, or cannot, reasonably cure the event that gives rise to the Constructive Termination.

5.3 Benefits Upon Termination. If the Executive’s employment by the Company is terminated during the Period of Employment for any reason by the Company or by the Executive, or upon or following the expiration of the Period of Employment (in any case, the date that the Executive’s employment by the Company terminates is referred to as the “Severance Date”), the Company shall have no further obligation to make or provide to the Executive, and the Executive shall have no further right to receive or obtain from the Company, any payments or benefits except as follows:

(a) The Company shall pay the Executive (or, in the event of his death, the Executive’s estate) any Accrued Obligations (as defined in Section 5.5);

(b) If, during the Period of Employment, the Executive’s employment with the Company terminates as a result of an Involuntary Termination (as defined in Section 5.5), the Executive shall be entitled to the following benefits:

(i) The Company shall pay the Executive (in addition to the Accrued Obligations), subject to tax withholding and other authorized deductions, an amount equal to one hundred percent (100%) of the Executive’s annualized Base Salary (as in effect immediately prior to the termination of the Executive’s employment). Such amount is referred to hereinafter as the “Severance Benefit.” The Company shall pay the Severance Benefit to the Executive in equal installments on a bi-weekly basis over a period of twelve (12) months following the Severance Date (the “Severance Period”).


Notwithstanding the foregoing provisions of this Section 5.3, if the Executive breaches his obligations under Section 6 of this Agreement at any time, from and after the date of such breach, the Executive will no longer be entitled to, and the Company will no longer be obligated to pay, any remaining unpaid portion of the Severance Benefit.

5.4 Exclusive Remedy. The Executive agrees that the payments contemplated by Section 5.3 (and any applicable acceleration of vesting of an equity-based award in accordance with the terms of such award in connection with the termination of the Executive’s employment) shall constitute the exclusive and sole remedy for any termination of his employment and the Executive covenants not to assert or pursue any other remedies, at law or in equity, with respect to any termination of employment. The Company and Executive acknowledge and agree that there is no duty of the Executive to mitigate damages under this Agreement. All amounts paid to the Executive pursuant to Section 5.3 shall be paid without regard to whether the Executive has taken or takes actions to mitigate damages.

5.5 Certain Defined Terms.

 

(a) As used herein, “Accrued Obligations” means:

(i) any Base Salary that had accrued but had not been paid (including accrued and unpaid vacation time) on or before the Severance Date; and

(ii) any Incentive Bonus payable pursuant to Section 3.2 with respect to any fiscal year in the Period of Employment preceding the year in which the Severance Date occurs to the extent earned by but not previously paid to the Executive; and

(iii) any reimbursement due to the Executive pursuant to Section 4.2 for expenses incurred by the Executive on or before the Severance Date.

(b) As used herein, “Cause” shall mean, as reasonably determined by the Board (excluding the Executive, if he is then a member of the Board), (i) any act of personal dishonesty taken by the Executive in connection with his responsibilities as an employee of the Company which is intended to result in substantial personal enrichment of the Executive and is reasonably likely to result in material harm to the Company, (ii) the Executive’s conviction of a crime which the Board reasonably believes has had or will have a material detrimental effect on the Company’s reputation or business, (iii) a willful act by the Executive which constitutes misconduct and is materially injurious to the Company, or (iv) continued violations by the Executive of the Executive’s obligations to the Company after there has been delivered to the Executive a written demand for performance from the Company which describes the basis for the Company’s belief that the Executive has violated his obligations to the Company.

(c) As used herein, “Constructive Termination” shall mean a resignation by the Executive within thirty (30) days after the occurrence of any of the following: (i) without the Executive’s express written consent, a material reduction of the Executive’s duties, position or responsibilities relative to the Executive’s duties, position or responsibilities in effect immediately prior to such reduction, or the removal of the Executive from such duties, position and responsibilities, unless the Executive is provided with substantially comparable duties, position and responsibilities; (ii) without the Executive’s express written consent, a material reduction of the facilities and perquisites (including without limitation office space, location and administrative support) available to the Executive immediately prior to such reduction; (iii) a reduction by the Company of the Executive’s Base Salary


or Incentive Bonus opportunity as in effect immediately prior to such reduction; (iv) a material reduction by the Company in the kind or level of employee benefits to which the Executive is entitled immediately prior to such reduction with the result that the Executive’s overall benefits package is materially reduced; or (v) without the Executive’s express written consent, the relocation of the Executive to a facility or a location more than fifty (50) miles from his current location.

(d) As used herein, “Disability” shall mean a physical or mental impairment which, as reasonably determined by the Board, renders the Executive unable to perform the essential functions of his employment with the Company, even with reasonable accommodation that does not impose an undue hardship on the Company, for more than 180 days in any 12-month period, unless a longer period is required by applicable law, in which case that longer period would apply.

(e) As used herein, “Involuntary Termination” shall mean a Constructive Termination or a termination of the Executive by the Company without Cause. For purposes of clarity, the term Involuntary Termination does not include a termination of the Executive’s employment due to the Executive’s death or Disability.

5.6. Notice of Termination. Any termination of the Executive’s employment under this Agreement shall be communicated by written notice of termination from the terminating party to the other party. The notice of termination shall indicate the specific provision(s) of this Agreement relied upon in effecting the termination.

6. Confidentiality; Non-Competition; Non-Solicitation.

6.1 Confidential Information.

The Executive hereby agrees at all times during the term of his or her employment and after termination, to hold in the strictest confidence, and not to use, except for the benefit of the Company Group, or to disclose to any person, corporation or other entity without written consent of the Company, any Confidential Information. The Executive understands that “Confidential Information” means any proprietary or confidential information of the Company Group, its affiliates, their clients, customers or partners, and the Company Group’s licensors, including, without limitation, technical data, trade secrets, research and development information, product plans, services, customer lists and customers (including, but not limited to, customers of the Company Group on whom the Executive called or with whom the Executive became acquainted during the term of his or her employment), supplier lists and suppliers, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, personnel information, marketing, finances, information about the suppliers, joint ventures, licensors, licensees, distributors and other persons with whom the Company Group does business, information regarding the skills and compensation of other employees of the Company Group or other business information disclosed to the Executive by or obtained by the Executive from the Company Group, its affiliates, or their clients, customers or partners either directly or indirectly in writing, orally or by drawings or observation of parts or equipment.

6.3 Conflicting Employment. The Executive hereby agrees that, during the term of his or her employment with the Company, he or she will not engage in any other employment, occupation, consulting or other business activity related to the business in which the Company Group is now involved or becomes involved during the term of the Executive’s employment, nor will the Executive engage in any other activities that conflict with his or her obligations to the Company without the prior written consent of the Company.


6.4 Non-Competition.

(a) The Executive hereby agrees that during the course of his or her employment and for a period of two (2) years immediately following the termination of his or her relationship with the Company for any reason, whether with or without good cause or for any or no cause, at the option either of the Company or his or herself, with or without notice, the Executive will not, without the prior written consent of the Company, (i) serve as a partner, employee, consultant, officer, director, manager, agent, associate, investor, or otherwise for, or lend his or her name (or any part, variant or formative thereof), (ii) directly or indirectly, own, purchase, organize or take preparatory steps for the organization of, (iii) build, design, finance, acquire, lease, operate, manage, invest in, work or consult for or otherwise affiliate himself or herself with, any business, in competition with or otherwise similar to the business of the Company Group, (iv) deal, directly or indirectly, in a competitive manner with any customers doing business with the Company Group, or (v) transfer, sell, assign, pledge, hypothecate, give, create a security interest in or lien on, place in trust (voting or otherwise), or in any other way dispose of any equity interest in the Company Group beneficially owned by the Executive, as the case may be, to any person which is competitive with any significant aspect of the business of the Company Group. The foregoing covenant shall cover the Executive’s activities in every part of the Territory in which he or she may conduct business during the term of such covenant as set forth above. “Territory” shall mean (i) the People’s Republic of China (including Hong Kong), (ii) Taiwan, (iii) the United States of America, and (iv) all other countries of the world; provided that, with respect to clauses (iii) and (iv) of this Section 6.4(a), the Company derives at least five percent (5%) of its gross revenues from such geographic area prior to the date of the termination of the Executive’s relationship with the Company.

(b) The Executive hereby acknowledges that he or she will derive significant value from the Company’s agreement to provide him or her with that Confidential Information of the Company Group to enable him or her to optimize the performance of his or her duties for the Company. The Executive hereby further acknowledges that his or her fulfillment of the obligations contained in this Agreement, including, but not limited to, his or her obligation neither to disclose nor to use the Confidential Information of the Company Group other than for the Company Group’s exclusive benefit and his or her obligation not to compete contained in subsection (a) above, is necessary to protect the Confidential Information of the Company Group and, consequently, to preserve the value and goodwill of the Company Group. The Executive hereby further acknowledges the time, geographic and scope limitations of his or her obligations under subsection (a) above are reasonable, especially in light of the Company Group’s desire to protect their Confidential Information, and that the Executive will not be precluded from gainful employment if he or she is obligated not to compete with the Company Group during the period and within the Territory as described above.

(c) The covenants contained in subsection (a) above shall be construed as a series of separate covenants, one for each city, county and state of any geographic area in the Territory. Except for geographic coverage, each such separate covenant shall be deemed identical in terms to the covenant contained in subsection (a) above. If, in any arbitration proceeding, the arbitration panel refuses to enforce any of such separate covenants (or any part thereof), then such unenforceable covenant (or such part) shall be eliminated from this agreement to the extent necessary to permit the remaining separate covenants (or portions thereof) to be enforced. In the event the provisions of subsection (a) above are deemed to exceed the time, geographic or scope limitations permitted by applicable law, then such provisions shall be reformed to the maximum time, geographic or scope limitations, as the case may be, then permitted by such law.


(d) The Executive hereby further agrees that he or she will be compensated by the Company in the total amount equal to the greater of (i) one month’s salary or (ii) the minimum amount of compensation required by applicable law (hereinafter referred to as the “Compensation”) upon the termination of his or her employment with the Company for the covenants that the Executive makes in this Section 6.4. The Compensation will be paid by four installments, of which the first installment equal to 1/4 of the total amount of the Compensation will be paid within three months after the employment is terminated and each of the other three installments equal to 1/4 of the total amount of the Compensation will be paid per three months thereafter.

6.5 Notification of New Employer. In the event that the Executive leaves the employ of the Company, The Executive hereby grants consent to notification by the Company to his or her new employer about his or her rights and obligations under this Agreement.

6.6 Non-Solicitation. The Executive hereby agrees that for a period of two (2) years immediately following the termination of his or her relationship with the Company for any reason, whether with or without cause, he or she shall not either directly or indirectly solicit, induce, recruit or encourage any employees of the Company Group to leave their employment, or take away such employees, or attempt to solicit, induce, recruit, encourage or take away employees of the Company Group and/or any suppliers, customers or consultants of the Company Group, either for his or herself or for any other person or entity.

6.7 Representations. The Executive hereby agrees to execute any proper oath or verify any proper document required to carry out the terms of this Agreement. The Executive hereby represents that the Executive’s performance of all the terms of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by the Executive in confidence or in trust prior to his or her employment by the Company. The Executive has not entered into, and hereby agrees that he or she will not enter into, any oral or written agreement in conflict with this Section 6.

7. Withholding Taxes. Notwithstanding anything else herein to the contrary, the Company may withhold (or cause there to be withheld, as the case may be) from any amounts otherwise due or payable under or pursuant to this Agreement such national, provincial, local or any other income, employment, or other taxes as may be required to be withheld pursuant to any applicable law or regulation.

8. Assignment. This Agreement is personal in its nature and neither of the parties hereto shall, without the consent of the other, assign or transfer this Agreement or any rights or obligations hereunder; provided, however, that in the event of a merger, consolidation, or transfer or sale of all or substantially all of the assets of the Company with or to any other individual(s) or entity, this Agreement shall, subject to the provisions hereof, be binding upon and inure to the benefit of such successor and such successor shall discharge and perform all the promises, covenants, duties, and obligations of the Company hereunder.

9. Number and Gender. Where the context requires, the singular shall include the plural, the plural shall include the singular, and any gender shall include all other genders.


10. Section Headings. The section headings of, and titles of paragraphs and subparagraphs contained in, this Agreement are for the purpose of convenience only, and they neither form a part of this Agreement nor are they to be used in the construction or interpretation thereof.

11. Governing Law. This Agreement shall be governed by and construed in accordance with the domestic laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than the State of New York.

12. Severability. If any provision of this Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or applications of this Agreement which can be given effect without the invalid provisions or applications and to this end the provisions of this Agreement are declared to be severable.

13. Entire Agreement. This Agreement embodies the entire agreement of the parties hereto respecting the matters within its scope. This Agreement supersedes all prior and contemporaneous agreements of the parties hereto that directly or indirectly bears upon the subject matter hereof (including, without limitation, any offer letter or previous employment agreement). Any prior negotiations, correspondence, agreements, proposals or understandings relating to the subject matter hereof shall be deemed to have been merged into this Agreement, and to the extent inconsistent herewith, such negotiations, correspondence, agreements, proposals, or understandings shall be deemed to be of no force or effect. There are no representations, warranties, or agreements, whether express or implied, or oral or written, with respect to the subject matter hereof, except as expressly set forth herein.

14. Modifications. This Agreement may not be amended, modified or changed (in whole or in part), except by a formal, definitive written agreement expressly referring to this Agreement, which agreement is executed by both of the parties hereto.

15. Waiver. Neither the failure nor any delay on the part of a party to exercise any right, remedy, power or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other or further exercise of the same or of any right, remedy, power or privilege, nor shall any waiver of any right, remedy, power or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to any other occurrence. No waiver shall be effective unless it is in writing and is signed by the party asserted to have granted such waiver.

16. Waiver of Jury Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT.

17. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon, and all of which together shall constitute one and the same instrument. This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties reflected hereon as the signatories. Photographic copies of such signed counterparts may be used in lieu of the originals for any purpose.


[The remainder of this page has intentionally been left blank.]

IN WITNESS WHEREOF, the Company and the Executive have executed this Agreement as of the Effective Date.

“COMPANY”

Tibet Pharmaceuticals, Inc.

 

By:  

/s/ Yu Hong

Name: Yu Hong
Title: Chairman of the Board

“EXECUTIVE”

 

By:  

/s/ Yu Hong

Name: Yu Hong
EX-99.01 4 dex9901.htm EXHIBIT 99.01 Exhibit 99.01

EXHIBIT 99.01

LOGO

Tibet Pharmaceuticals Announces New CEO

Tibet’s Chairman, Hong Yu, Replaces Taylor Guo as CEO of Tibet Pharmaceuticals

SHANGRI-LA COUNTY, CHINA — June 10, 2011 — Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced that effective as of June 6, 2011 its Chairman, Mr. Hong Yu, replaces Mr. Taylor Guo as CEO of Tibet Pharmaceuticals.

Taylor Guo leaves Tibet Pharmaceuticals to pursue other interests while Hong Yu, the Chairman of Tibet Pharmaceuticals and founder of its operating entity in China, takes a more active role in the Company’s development initiatives and investor outreach. Taylor Guo will remain a director of the Company for the foreseeable future.

Mr. Yu stated, “As I take over the position of CEO we would like to thank Taylor Guo for his commitment and dedication to the firm both before and after Tibet Pharmaceuticals’ IPO in January. Taylor will continue to advise the company as an active member of our Board of Directors. Moving forward, one of my top priorities will be putting various measures in place to enhance our communication levels with the investor community, in addition to implementing initiatives to actively support shareholder value.”

Mr. Yu went on to say, “We remain confident in the long-term prospects of China’s healthcare market and, in particular, the growth potential of Tibet Pharmaceuticals as we continue to report strong sales and earnings across our various pharmaceutical products.”

About Tibet Pharmaceuticals, Inc.

Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ: TBET) is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals’ products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company’s 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.


For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Research Report, Investor Portal and Overview Video.

For more information on Tibet Pharmaceuticals, please visit:

www.tibetpharmaceuticals.com

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. Specifically, references herein to contemplated growth in company revenues and/or earnings are forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Financial Communications Contact:

Trilogy Capital Partners – Asia

Darren Minton, President

Toll-free: 800-592-6067

info@trilogy-capital.com

GRAPHIC 5 g196651g36j60.jpg GRAPHIC begin 644 g196651g36j60.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH MHH`****`"BBB@`HHI*`%HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!KNL: M%W8*JC))[5RFJ:O)?2%(R4@!X`X+>YJ[XCOB-ME&?]J3^@K/TO2VU)WR^R-. MK`9.?2O$QM>=6I]7I?,B3OHC1T7669EM;ILD\)(?Y&M^N)OK-["[:%CG'*L. MXKIM&OC>V0+G,D?RO[^AK7`8F3;H5-T$7T9H4445ZQ84444`%%%%`!114HKG%D!.#4T*-),J*2&8X M!%W]M;K<5];G9W.MV-L2IE\QAVC&:I-XHBS\MJY'NP%<[17 M1/,J\G[NA7,SJK+7H;RX6#R7C9^A)!%:M<5IA(U.VQ_ST%=K7JX#$3K0;GNF M5%W"BBD9@JEF(``R2>U>@45M1U&UTNT:ZNY-B`A0`,L['HJ@84!#.\KCT4'Y5X!(!)J:74K2WA_X2O6"Q3[FF6H7< M^#P"J]Y'_0$#CFK/AK2[]KF;Q!KBA=3O%V)`#E;.'.1&#W/=CW/TH`VK/3K+ M3X_+L[6*!>_EH!GZGO4&IRP/Y=A):I>/K%_>PZ=92 MW@`'$YY'E@TV026;2-N9(F_@)/)`R,5W=6U\?MXELYD$5W:^1>0 ML#DD8VLOY`$&NDH`*Y2_UZ_UK5Y="\,NB&W.+[4V7>EL?[B#H\GZ#O4'CGQ% M>13VGA?07_XG.J\"0<_9HOXI#^&$/#=GXR7WEW<\<5S(`&DC5RH)QQV-;]5=,T^#2M, MMM/M@1%;QB-<]3@=3[GK5J@`HHHH`**J:CJEAI%K]JU&\AM(-P7S)G"KD]!D MUE'QYX2`)_X2+3N.?]>M`&Q>W]GIML;F^NH;:%3@R3.%4'ZFIU8,H92"",@C MO7BIU[2OB/XV6?6=3M[/P_IL@%K:3RA6NGSP2OOW]L#N:]J`"@```#@`=J`% MHHHH`****`"BBB@`HHHH`BN(_.MI8_[Z$?I7#$$'!ZBN^KCM=M39Z@Q`_=R_ M.I_F*\?-*3E&,UT(GW*-:&E:NC]EA%NS'@#&"?H:I-IGV#6[5%):)W!0GK[BN9 M9VCERI*D'(([5W=JXU2QL;O`WJP8_7!!KUJ?+B5\*35FK=AQ?,2_N M+V[:YFE8MVP>%]A7/.A3HQ]]7;Z;$NRW+$L;PR-'(I5U."#VIN13KVZ-P\3. MVYUB57;U/^<56WUYTH)2:6P7-;1(_-U6''1,L?P%=A6#X8LRD#WCC!E^5/\` M=]?\^E;U?19?2=.CKUU-8[!4<\*7%O)!)G9*A1L'!P1@UQ.F^/M3UWQM/I&D M:'YVEV#'WNWRW^I)_J[=.A`;U]Q]![ M`'06-^GBOQ)*\!WZ5HTFQ7'W;BZQR1ZA`?\`OHY["NIK,T'1;+PUH=OI=F`L M%LF"S<%CU+'W)YJ>+6-,GO/L4.HVLMS@MY*3*SX'4X!S0!1C\46<84GU(.:T[R[AL+*>\N&V0P1M([>B@9-$-E:V]Q/[E\0ZV@&IW M:[(X`_=CW/L*RO`?A06^D:3J6I7"7DT-JGV*-!B&U5ESE1W(+G45O$CN+"W91:ZC';O M`MQGJ`K$]/6NPDD2*-I)'5$499F.`![F@!)(XY5VR(KCKAAD5Y+X\U`^,?$] MOX#\/K$J!]VH7"(,*%Y(SZ+W]3@5UUWK]WXIF?2O"LC+;YVW6L`?NXAW6(_Q MO[C@5@_"O1K33_$OBLI'MEM[L6R*QRRQC)!)[[L`D]\4`=YI6@Z;H^F6^GVE MK&L-N@1,J"3[D^I/-:-%%`!1110`4444`%%%%`!116=KE]/I^FO/;QEWSC=V M3W-3.2C%R?03=ED:\L:Y?5M??4XO)%ND:`Y4GEA6-),\L MC22.7=CDL3DFF[Z\.OBJE6Z6B.>51L1II%.":07#COFAB&+(1T.:YE%/< MR;9,\P<9Q@BNT\'3>9H[)G_5RD?G@UP9W>AKK?`L_P#Q]V[<'Y7'\C_2NW!V MC51=*7ODGC6]V16]FI^\3(WT'`_K7*BXV+M4?B:T/%EP;C7I@,E8@$'Y9/ZF ML8*Y[5.)M.HVR9R;DRA%=M'&3B[3U1M&K;H:?J4YN7@$HCEAD/WMI;Y64 M^F01[U?DUK7&7%MX6N"__3>ZA11^(9C^E;4+M)"DCQF-F4$H>JGTJ2O9.DXN M]\->)_%`\K7]8BT[3V^]8Z7G=(/1Y6Y_`#%='HN@Z7X=L%L=*LX[:$=0HY8^ MK'J3]:=KFJIH>B7>J20M,MK$9#&AP6QV%^.E:A:7VES:5-<:;<3V!M#GF::_CN=1=F+?Z9=22J/8*3MQ^%8FA_#_5 M/#]Q=G3-4TZR6XF=_.BTX-,5)R%R6V@#I@#%:.D^*;P106M_HUQ%*VG?:[?; M,LKSA0H((XVM\PXR>O6F'Q\D%KJ+W6GJ)K"V6Y,5M=),&5FV[=PZ,".GZT`6 M_P#A#OM7_(7U[5=14_>B,XAC;ZK&%S^)K3A\/Z/;Z5-I<&G6\5G.A26%(PH< M$8.<=3[UBW7C#4K>5X/^$;F,\5H;R6-KI!LBW,.O/S87./UJ2S\8RW$C++HM MS$)+$WUH%D5WN(QCC:/NM\R\$]^O%`%6Q\':YI%M_9FF>+)8=+7(CCDM4DFA M7^ZLA/Y9!Q3[;P+/I8DBT7Q+J5A;RN9)8R(YBTA^\^YU)!/4^].C\=PI#?\` MVVT5)K**.3R[:Y6<2;V**H88PV[C!],'.:`&#P/;3C&J:QK&I>JS7K(A_X#'M%8/8-MS'-:Q_:++YUVW7B:UMEZ8L MM/`/X%V;^5.7P-IL[J^KW5]K+*C<$CUJC_PDQU>YT:>$/!Y>J36]Q'%+YBN5@=N&7AUZ$5>\.>+_`/A()T6. MP"0RQEUDCN%E,>#]V51S&WMSW%`"CP[KTXVWWC"[9.XM+6*`_GAC711IY<:I MN9MH`W,Q? MD6VDP>7"-SM]^1NK5?HKKI8>%+5;FL: M:B8>M^&H=3)G@80W/H:2>8/6CS!ZUZE+I>GS',EE`Q]3&,TD>EZ?"K-84E'4****ZC4P_&MM->>#=5MK>*2666W942,98GV'K5.3P MA,+.6UMSY"Q^4)%VLYP?F;``SP.O'-=110!SNJ^$(-5ACBDO9H MA'I\ECF,`$A]GS?^.#CW-9Y\`/*+@3:L`+FT%JZ06:1(JAMRE5'0YSGKG/;% M=E10!DW6@QW6H7=X;AU-U8?8BH48498[OK\WZ5GW_@J"_LHK5[Z:,1Z8=/#( M`"02AW?^.#CH`1*;DW6J9%S;+`R6]JD*QE'WQN@'0AN>Y36-9FNGEC1(C%$(DA*L'#A,D%MP')[#&*Z6B@#F9?",UW87<%YJS- M+.L8C>"W6)(2C;E8)SD[@,Y/3CBHY?!D]W;:J+[6I9[G4XH8VF$"JL?EL67: MH[9/0G\:ZJB@#F[OPA]KEGNWU&1+V26WGCG2,`1RQ*5#;>X()R/0U#?>#;G4 MHQ)>ZT\]VMRDZEX`T"[5*A?))QCYB>NM>` M")8\.T1C8#;T'.1Z8J33/"#V>L6VI76HB[EM(WCC<6ZQR2!@!F5P?WAP/;GF MNEHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** $*`/_V3\_ ` end